Source: International Congress 2015 – IPF: from bench to bedside
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Lian Liu (Chengdu, China), Lian Liu, Hao Wang, Hao Wang, Xiaoou Li, Fuqiang Wen. Etablishing rhesus model of pulmonary fibrosis (PF) for the new drug evaluation. Eur Respir J 2015; 46: Suppl. 59, 3050

Member's Comments

No comment yet.

Related content which might interest you: ILD-India registry: Idiopathic pulmonary fibrosis (IPF) and connective tissue disease (CTD) associated interstitial lung disease (CTD-ILD) Source: International Congress 2016 – Clinical aspects of ILD Year: 2016 The ratio AGE/RAGE is increased in idiopathic pulmonary fibrosis Source: International Congress 2015 – Connective tissue disorders Year: 2015 Genomic comparison of fibrotic rheumatoid arthritis-associated ILD and idiopathic pulmonary fibrosis Source: International Congress 2015 – Connective tissue disorders Year: 2015 Significance of histopathologic features suggesting connective tissue disease in idiopathic pulmonary fibrosis Source: International Congress 2015 – Connective tissue disorders Year: 2015 Clinical efficacy of pirfenidone in patients with severe fibrosing interstitial pneumonia Source: International Congress 2015 – Treatment of IPF Year: 2015 Addition of respiratory hospitalizations 24weeks prior to the ILD-GAP model to predict mortality in chronic interstitial lung disease Source: International Congress 2016 – Clinical aspects of ILD Year: 2016 A multicentre evaluation of inter-multidisciplinary team agreement for diagnosis in diffuse lung disease Source: International Congress 2016 – Epidemiological and clinical data regarding the modern management of chronic lung diseases Year: 2016 A multicentre evaluation of inter-multidisciplinary team agreement for predicted disease behaviour and management strategy in diffuse lung disease Source: International Congress 2016 – Epidemiological and clinical data regarding the modern management of chronic lung diseases Year: 2016 Relevance of the expert ILD clinical-radiological evaluation of referred cases to the MDT Source: International Congress 2016 – Clinical aspects of ILD Year: 2016 Fibulin-1 is a novel biomarker of disease severity in pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Pulmonary hypertension in interstitial lung disease Source: Eur Respir J 2008; 31: 1357-1367 Year: 2008 The RANKL-OPG balance in pulmonary fibrosis Source: International Congress 2015 – Connective tissue disorders Year: 2015 Study of factors affecting mortality in ILD cases over 2 years Source: International Congress 2016 – Clinical aspects of ILD Year: 2016 Serum surfactant protein D (SP-D) and annual decline of diffusion capacity are prognostic factors for combined pulmonary fibrosis with emphysema (CPFE) in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Clinical respiratory physiology in different diseases Year: 2013 Lysyl oxidases in idiopathic pulmonary fibrosis: A key participant in collagen I matrix remodelling Source: International Congress 2015 – Airway remodelling: recent developments Year: 2015 Using the ILD-GAP model to predict mortality in chronic interstitial lung disease Source: International Congress 2015 – IIPs: orphan Year: 2015 Forced oscillation technique in patient with scleroderma, idiopathic pulmonary fibrosis (IPF) and connective tissue diseases Source: Eur Respir J 2002; 20: Suppl. 38, 31s Year: 2002 Interstitial lung disease Source: Eur Respir Rev 2013; 22: 26-32 Year: 2013 Efficacy of pirfenidone in idiopathic pulmonary fibrosis: A single center experience Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016